522607-99-4

Upstream product

• 844665-61-8 9-(3-C-azidomethyl-3-deoxy-β-D-ribofuranosyl)-N⁶-(3-iodobenzyl)adenine 
• 146035-68-9 [(3aR,5S,6R,6aR)-6-(azidomethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-dimethylsilane 
• 630105-33-8 9-(2-O-acetyl-3-C-azidomethyl-3-deoxy-5-O-toluoyl-β-D-ribofuranose)-6-chloropurine 
• 522607-98-3 1,2-di-O-acetyl-3-C-azidomethyl-3-deoxy-5-O-toluoyl-D-ribofuranose 
• 522607-97-2 3-C-azidomethyl-3-deoxy-1,2-O-isopropylidene-5-O-toluoyl-α-D-ribofuranose 
• 362600-12-2 3-C-azidomethyl-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 

Relevant academic research and scientific papers

Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety

In this paper we investigated the influence on affinity, selectivity and intrinsic activity upon modification of the adenosine agonist scaffold at the 3′- and 5′-positions of the ribofuranosyl moiety and the 2- and N6-positions of the purine ba

Modeling the Adenosine Receptors: Comparison of the Binding Domains of A2A Agonists and Antagonists

A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding